ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
Returns on capital
ALX Oncology Holdings Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-391.4%
avg 768.3%
ROIC
-262.0%
avg -126.9%
ROA
-172.2%
avg -88.2%
Analysis
ROA is currently the strongest return metric at -172.2% versus its period average of -88.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jason W. Lettmann | Chief Executive Officer & Director | USD 1.02M | 49 | — | — |
Harish Shantharam | Chief Financial Officer | USD 642.87K | 45 | 303.00K | 0.23% |
Shelly Wong | Senior Vice President of Finance & Chief Accounting Officer | USD 578.47K | 50 | 87.83K | 0.07% |
Barbara J. Klencke | Chief Medical Officer | USD 262.58K | 69 | — | — |
Athanasios Tsiatis | Senior Vice President of Clinical Development | — | — | — | — |
Lin Yeong-Liang | Senior Vice President of Drug Safety & Pharmacovigilance | — | — | — | — |
Michael Listgarten | General Counsel | — | — | — | — |
Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | — | — |
Sue Naim | Senior Vice President of Clinical Operations | — | — | — | — |
Venita De Almeida | Vice President & Head of Research Program Development | — | — | — | — |
Jeff E. Knight | Chief Development & Operating Officer | — | 55 | 800.00K | 0.59% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$5.00M
Sells
7
$42,587.63
Net Transaction Value
+$4.96M
Net buying
Most Active
Pinto Shelly
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 17, 26Aug 17, 2026 | Lettmann Jason Direct | Sell | $4.3K$4,303.90 |
| Aug 17, 26Aug 17, 2026 | Wong Shelly Direct | Sell | $1.1K$1,105.89 |
| Jul 1, 26Jul 1, 2026 | Wong Shelly Direct | Sell | $2.9K$2,864.16 |
| Mar 19, 26Mar 19, 2026 | Lettmann Jason Direct | Sell | $26.7K$26,714.87 |
| Mar 19, 26Mar 19, 2026 | Pinto Shelly Direct | Sell | $2K$1,959.51 |
| Feb 18, 26Feb 18, 2026 | Pinto Shelly Direct | Sell | $1.3K$1,282.55 |
| Feb 2, 26Feb 2, 2026 | GOODMAN COREY S Indirect | Buy | $5M$4,999,999.41 |
| Jan 6, 26Jan 6, 2026 | Pinto Shelly Direct | Sell | $4.4K$4,356.75 |
Summary
Insiders reported 1 buys worth $5.00M and 7 sells worth $42,587.63 over the last 12 months. That adds up to net buying of $4.96M. Pinto Shelly was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does ALX Oncology Holdings Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ALXO's management, answered from reported figures.
Who manages ALXO?
ALX Oncology Holdings Inc. (ALXO) lists 11 active executives. The top listed executive is Athanasios Tsiatis, Senior Vice President of Clinical Development.
Are ALXO insiders buying or selling?
Recent insider activity shows net buying of $24.04M.
Continue the stock analysis
Jump to another research area for this company.